Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Type 2 Diabetes | Research

A higher TyG index level is more likely to have enhanced incidence of T2DM and HTN comorbidity in elderly Chinese people: a prospective observational study from the reaction study

Authors: Wanlu Su, Jie Wang, Kang Chen, Wenhua Yan, Zhengnan Gao, Xulei Tang, Qin Wan, Zuojie Luo, Guang Ning, Yiming Mu

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Background

Triglyceride glucose index (TyG index) was related with both type 2 diabetes (T2DM) and hypertension (HTN). Prospective studies linking the TyG index to the incidence of T2DM and HTN comorbidity remain unclear. This study aimed to to explore the longitudinal association between TyG and new-onset T2DM with HTN.

Methods

4,434 subjects (1249 males and 3185 females) without initial T2DM and HTN were followed up for 7 years. This study was conducted from November 2011 to August 2018 in the Gucheng, Laoshan and Jinding communities of Beijing. The incidence of T2DM with HTN during the 7-year follow-up was identified as the endpoint. The TyG index was divided into four quartiles: the < 25% level, the 25–50% level, the 50–75% level and the ≥ 75% level. The relationships between the TyG index and T2DM with HTN were evaluated by Cox proportional hazards regression models.

Results

During 7 years, the augmented trend of T2DM with HTN was observed in the participants. After adjusting for all confounding factors, compared with those in the lowest quartile of TyG index, the population in the highest quartile of TyG index had a higher risk of T2DM with HTN (hazard ratio (HR), 2.878; 95% confidence intervals (95% CI), 1.230–6.731, P = 0.015), however, the association remained significant only in the female population (HR 2.753, 95% CI, 1.061–7.139, p = 0.037). The TyG had superior predictive ability of increased risk of T2DM with HTN for the populations of older age (≥ 65 years) (HR 2.694, 95% CI 1.212–5.989, p = 0.015), higher eGFR (≥ 90 mL/(min·1.73 m2)) (HR 2.603, 95% CI 1.164–5.818, p = 0.020) or obesity (BMI ≥ 28 kg/m2) (HR 2.547, 95% CI 1.001–6.478, p = 0.020).

Conclusion

A population with a higher TyG index level was more likely to have an enhanced incidence of T2DM and HTN comorbidity. TyG index could have the significance of clinical in early protection against T2DM with HTN.
Literature
1.
go back to reference GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRef GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59.CrossRef
2.
go back to reference Li Y, Teng Di, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: national cross sectional study. BMJ. 2020;369:997.CrossRef Li Y, Teng Di, Shi X, Qin G, Qin Y, Quan H, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American diabetes association: national cross sectional study. BMJ. 2020;369:997.CrossRef
3.
go back to reference Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672–6.PubMedCrossRef Kannel WB, D’Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672–6.PubMedCrossRef
4.
go back to reference Gitt AK, Schmieder RE, Duetting E, Bramlage P, Schneider S, Tschöpe D, DIALOGUE Study. Group Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice—study rationale and protocol of DIALOGUE. Cardiovasc Diabetol. 2012;2012(11):148.CrossRef Gitt AK, Schmieder RE, Duetting E, Bramlage P, Schneider S, Tschöpe D, DIALOGUE Study. Group Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice—study rationale and protocol of DIALOGUE. Cardiovasc Diabetol. 2012;2012(11):148.CrossRef
5.
go back to reference Bramlage P, Binz C, Gitt AK, Krekler M, Plate T, Deeg E, et al. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis)—study protocol and patient characteristics at baseline. Cardiovasc Diabetol. 2010;9:53.PubMedPubMedCentralCrossRef Bramlage P, Binz C, Gitt AK, Krekler M, Plate T, Deeg E, et al. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis)—study protocol and patient characteristics at baseline. Cardiovasc Diabetol. 2010;9:53.PubMedPubMedCentralCrossRef
6.
go back to reference Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005;42:S17–25.PubMedCrossRef Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol. 2005;42:S17–25.PubMedCrossRef
7.
go back to reference O’Meara JG, Kardia SR, Armon JJ, Brown C, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004;164:1313–8.PubMedCrossRef O’Meara JG, Kardia SR, Armon JJ, Brown C, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med. 2004;164:1313–8.PubMedCrossRef
8.
go back to reference Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, et al. Effects of 6‐month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly‐diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol. 2016;15:121.PubMedPubMedCentralCrossRef Sawada T, Tsubata H, Hashimoto N, Takabe M, Miyata T, Aoki K, et al. Effects of 6‐month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly‐diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial. Cardiovasc Diabetol. 2016;15:121.PubMedPubMedCentralCrossRef
9.
go back to reference Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med. 2005;165:2420–7.PubMedCrossRef Sesso HD, Buring JE, Chown MJ, Ridker PM, Gaziano JM. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med. 2005;165:2420–7.PubMedCrossRef
10.
go back to reference Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension. 2006;47:45–50.PubMedCrossRef Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension. 2006;47:45–50.PubMedCrossRef
11.
go back to reference Memon AR, Shaikh F, Memon ZA, Majeed Adnan BA. Assessment of lipid profile and serum total protien in patients of hypertension. Ann Pak Inst Med Sci. 2017;13:246–8. Memon AR, Shaikh F, Memon ZA, Majeed Adnan BA. Assessment of lipid profile and serum total protien in patients of hypertension. Ann Pak Inst Med Sci. 2017;13:246–8.
12.
go back to reference Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–44.PubMedCrossRef Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434–44.PubMedCrossRef
13.
go back to reference Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRef Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–52.PubMedCrossRef
14.
go back to reference Berry J, Keebler ME, McGuire DK. Diabetes mellitus and cardiovascular disease. Pandora’s box has been opened Herz. 2004;29:456–62.PubMed Berry J, Keebler ME, McGuire DK. Diabetes mellitus and cardiovascular disease. Pandora’s box has been opened Herz. 2004;29:456–62.PubMed
15.
go back to reference Janghorbani M, Bonnet F, Amini M. Glucose and the risk of hypertension in first- degree relatives of patients with type 2 diabetes. Hypertens Res. 2015;38:349–54.PubMedCrossRef Janghorbani M, Bonnet F, Amini M. Glucose and the risk of hypertension in first- degree relatives of patients with type 2 diabetes. Hypertens Res. 2015;38:349–54.PubMedCrossRef
16.
go back to reference Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMedCrossRef Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.PubMedCrossRef
17.
go back to reference Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.PubMedPubMedCentralCrossRef Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.PubMedPubMedCentralCrossRef
19.
go back to reference Cheung BM, Wat NM, Tso AW, Tam S, Thomas GN, Leung GM, et al. Association between raised blood pressure and dysglycemia in Hong Kong Chinese. Diabetes Care. 2008;31:1889–91.PubMedPubMedCentralCrossRef Cheung BM, Wat NM, Tso AW, Tam S, Thomas GN, Leung GM, et al. Association between raised blood pressure and dysglycemia in Hong Kong Chinese. Diabetes Care. 2008;31:1889–91.PubMedPubMedCentralCrossRef
20.
go back to reference Hotmisligli GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.CrossRef Hotmisligli GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.CrossRef
21.
go back to reference Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich). 2011;13:238–43.PubMedCrossRef Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich). 2011;13:238–43.PubMedCrossRef
22.
go back to reference De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–23. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214–23.
24.
go back to reference Guerrero-Romero F, Simental-Mendia LE, Gonzalez-ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metabol. 2010;95:3347–51.CrossRef Guerrero-Romero F, Simental-Mendia LE, Gonzalez-ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metabol. 2010;95:3347–51.CrossRef
25.
go back to reference Vasques AC, Novaes FS, de Oliveira MS, Souza JR, Yamanaka A, Pareja JC, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93:e98–100.PubMedCrossRef Vasques AC, Novaes FS, de Oliveira MS, Souza JR, Yamanaka A, Pareja JC, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93:e98–100.PubMedCrossRef
26.
go back to reference Espinel-Bermúdez MC, Robles-Cervantes JA, del Sagrario L, Villarreal-Hernández JP, Villaseñor-Romero SO, Hernández-González MG-O, et al. Insulin resistance in adult primary care patients with a Surrogate Index Guadalajara. J Investig Med. 2015;63:247–50.PubMedPubMedCentralCrossRef Espinel-Bermúdez MC, Robles-Cervantes JA, del Sagrario L, Villarreal-Hernández JP, Villaseñor-Romero SO, Hernández-González MG-O, et al. Insulin resistance in adult primary care patients with a Surrogate Index Guadalajara. J Investig Med. 2015;63:247–50.PubMedPubMedCentralCrossRef
27.
go back to reference Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The prod- uct of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304.PubMedCrossRef Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The prod- uct of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304.PubMedCrossRef
28.
go back to reference Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST- segment elevation acute coronary syndrome. Dis Markers. 2019;2019:6891537.PubMedPubMedCentralCrossRef Mao Q, Zhou D, Li Y, Wang Y, Xu SC, Zhao XH. The triglyceride-glucose index predicts coronary artery disease severity and cardiovascular outcomes in patients with non-ST- segment elevation acute coronary syndrome. Dis Markers. 2019;2019:6891537.PubMedPubMedCentralCrossRef
29.
go back to reference Jian S, Su-Mei N, Xue C, Jie Z, Xue-sen W. Association and interaction between triglyceride– glucose index and obesity on risk of hypertension in middle-aged and elderly adults. Clin Exp Hypertens. 2017;39:732–9.PubMedCrossRef Jian S, Su-Mei N, Xue C, Jie Z, Xue-sen W. Association and interaction between triglyceride– glucose index and obesity on risk of hypertension in middle-aged and elderly adults. Clin Exp Hypertens. 2017;39:732–9.PubMedCrossRef
30.
go back to reference Lambrinoudaki I, Kazani MV, Armeni E, Georgiopoulos G, Tampakis K, Rizos D, et al. The TyG index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women. Hear Lung Circ. 2018;27:716–24.CrossRef Lambrinoudaki I, Kazani MV, Armeni E, Georgiopoulos G, Tampakis K, Rizos D, et al. The TyG index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women. Hear Lung Circ. 2018;27:716–24.CrossRef
31.
go back to reference Ning G. Risk evaluation of cancers in Chinese diabetic individuals: a longitudinal (REACTION) study. J Diabetes. 2012;4:172–3.PubMedCrossRef Ning G. Risk evaluation of cancers in Chinese diabetic individuals: a longitudinal (REACTION) study. J Diabetes. 2012;4:172–3.PubMedCrossRef
32.
go back to reference Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–44.PubMedCrossRef Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–44.PubMedCrossRef
33.
go back to reference Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagno- sis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.PubMedCrossRef Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagno- sis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.PubMedCrossRef
34.
go back to reference 2016 Chinese guideline for the management of dyslipidemia in adults. Chin J Health Manage. 2017; 11:1 2016 Chinese guideline for the management of dyslipidemia in adults. Chin J Health Manage. 2017; 11:1
35.
go back to reference Mohd Nor NS, Lee S, Bacha F, Tfayli H, Arslanian S. Triglyceride glucose index as a surrogate measure of insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes mellitus: com- parison with the hyperinsulinemic-euglycemic clamp. Pediatr Diabetes. 2016;17:458–65.PubMedCrossRef Mohd Nor NS, Lee S, Bacha F, Tfayli H, Arslanian S. Triglyceride glucose index as a surrogate measure of insulin sensitivity in obese adolescents with normoglycemia, prediabetes, and type 2 diabetes mellitus: com- parison with the hyperinsulinemic-euglycemic clamp. Pediatr Diabetes. 2016;17:458–65.PubMedCrossRef
36.
go back to reference Zhu B, Wang J, Chen K, Yan W, Wang A, Wang W, Gao Z, Tang X, Yan L, Wan Q, Luo Z, Qin G, Chen L, Mu Y. A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study. Cardiovasc Diabetol. 2020;19:112.PubMedPubMedCentralCrossRef Zhu B, Wang J, Chen K, Yan W, Wang A, Wang W, Gao Z, Tang X, Yan L, Wan Q, Luo Z, Qin G, Chen L, Mu Y. A high triglyceride glucose index is more closely associated with hypertension than lipid or glycemic parameters in elderly individuals: a cross-sectional survey from the Reaction Study. Cardiovasc Diabetol. 2020;19:112.PubMedPubMedCentralCrossRef
37.
go back to reference Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, et al. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019;18:95.PubMedPubMedCentralCrossRef Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, et al. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019;18:95.PubMedPubMedCentralCrossRef
38.
go back to reference Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, Pastrana- Delgado J, Martínez JA. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46:189–97.PubMedCrossRef Sánchez-Íñigo L, Navarro-González D, Fernández-Montero A, Pastrana- Delgado J, Martínez JA. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46:189–97.PubMedCrossRef
39.
go back to reference Ato D, Sawayama T. Factors associated with high brachial-ankle pulse wave velocity in non-hypertensive and appropriately treated hyperten- sive patients with atherosclerotic risk factors. Vasc Health Risk Manag. 2017;13:383–92.PubMedPubMedCentralCrossRef Ato D, Sawayama T. Factors associated with high brachial-ankle pulse wave velocity in non-hypertensive and appropriately treated hyperten- sive patients with atherosclerotic risk factors. Vasc Health Risk Manag. 2017;13:383–92.PubMedPubMedCentralCrossRef
40.
go back to reference Kotchen TA, Grim CE, Kotchen JM, et al. Altered relationship of blood pressure to adiposity in hypertension. Am J Hypertens. 2008;21:284–9.PubMedCrossRef Kotchen TA, Grim CE, Kotchen JM, et al. Altered relationship of blood pressure to adiposity in hypertension. Am J Hypertens. 2008;21:284–9.PubMedCrossRef
42.
go back to reference Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovas- cular disease development. Nat Rev Endocrinol. 2014;10:293–302.PubMedCrossRef Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovas- cular disease development. Nat Rev Endocrinol. 2014;10:293–302.PubMedCrossRef
43.
go back to reference Takagi M, Tanaka Y, Yamasaki Y, et al. Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics. Am J Physiol Endocrinol Metab. 2003;284:E1022–6.PubMedCrossRef Takagi M, Tanaka Y, Yamasaki Y, et al. Responsiveness of insulin-induced cardiac sympathetic nerve activation associates with blood pressure regulation in diabetics. Am J Physiol Endocrinol Metab. 2003;284:E1022–6.PubMedCrossRef
44.
go back to reference Vasques ACJ, Novaes FS, da Saúde M, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93:98100.CrossRef Vasques ACJ, Novaes FS, da Saúde M, et al. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93:98100.CrossRef
45.
go back to reference Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab. 1997;82:414–7.PubMedCrossRef Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab. 1997;82:414–7.PubMedCrossRef
46.
go back to reference Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care. 2002;25:127–33.PubMedCrossRef Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care. 2002;25:127–33.PubMedCrossRef
47.
go back to reference Perissinotto E, Pisent C, Sergi G, Grigoletto F. ILSA Working Group (Italian Longitudinal Study on Ageing). Anthropometric measurements in the elderly: age and gender differences. Br J Nutr. 2002;87:177–86.PubMedCrossRef Perissinotto E, Pisent C, Sergi G, Grigoletto F. ILSA Working Group (Italian Longitudinal Study on Ageing). Anthropometric measurements in the elderly: age and gender differences. Br J Nutr. 2002;87:177–86.PubMedCrossRef
48.
go back to reference Gharipour M, Sadeghi M, Hosseini M, Andalib E, Boroujeni MB, Sarrafzadegan N. Effect of age on the phenotype of metabolic syndrome in developing country. Adv Biomed Res. 2015;4:103.PubMedPubMedCentralCrossRef Gharipour M, Sadeghi M, Hosseini M, Andalib E, Boroujeni MB, Sarrafzadegan N. Effect of age on the phenotype of metabolic syndrome in developing country. Adv Biomed Res. 2015;4:103.PubMedPubMedCentralCrossRef
Metadata
Title
A higher TyG index level is more likely to have enhanced incidence of T2DM and HTN comorbidity in elderly Chinese people: a prospective observational study from the reaction study
Authors
Wanlu Su
Jie Wang
Kang Chen
Wenhua Yan
Zhengnan Gao
Xulei Tang
Qin Wan
Zuojie Luo
Guang Ning
Yiming Mu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-024-01258-3

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.